

## ASX Announcement

### Results of Annual General Meeting

---

**23 November 2021** – Race Oncology Limited (**Race** or the **Company**) (ASX: RAC) advises that its Annual General Meeting of Shareholders was held today at 11.00 am (AEDT).

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that the details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

-ENDS-

#### About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene<sup>®</sup>.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Zantrene.

Learn more at [www.raceoncology.com](http://www.raceoncology.com).

#### Release authorised by:

Phil Lynch, CEO/MD on behalf  
of the Race Board of Directors  
[phillip.lynch@raceoncology.com](mailto:phillip.lynch@raceoncology.com)

#### Media contact:

Jane Lowe  
+61 411 117 774  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)

# Disclosure of Proxy Votes

## Race Oncology Limited

Annual General Meeting 2021

Tuesday, 23 November 2021



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of Remuneration Report	P	23,336,291	22,827,379 97.82%	4,600 0.02%	36,497	504,312 2.16%	25,031,347 99.98%	4,600 0.02%	36,497
2 Election of Director – Mary Harney	P	42,571,818	42,070,742 98.82%	500 0.00%	72,313	500,576 1.18%	44,269,474 100.00%	2,000 0.00%	72,313
3 Re-election of Director – Dr Daniel Tillett	P	42,625,712	42,137,300 98.85%	500 0.00%	18,419	487,912 1.14%	44,324,868 100.00%	500 0.00%	18,419
4 Adoption of Incentive Option Plan	P	23,017,714	22,358,654 97.14%	154,167 0.67%	355,074	504,893 2.19%	24,521,082 99.33%	165,161 0.67%	386,201
5 Increase in Total Aggregate Remuneration for Non-Executive Directors	P	23,323,382	22,582,573 96.82%	236,247 1.01%	49,406	504,562 2.16%	24,688,170 98.94%	263,741 1.06%	120,533

